Relmada Therapeutics has acquired complete worldwide ownership rights to Sepranolone from Sweden-based Asarina Pharma.

Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed ...

Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from Asarina Pharma AB Phase 2a results signaled improvement ...

US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on an acquisition, study results ...

Inc., a pharmaceutical company currently trading at $0.39 and showing a significant 89% decline over the past year according to InvestingPro data, has been alerted by the Nasdaq Stock Market of ...

Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Free Report) saw a large decline in short interest during the month of January.As of January 15th, there was short interest totalling 1,250,000 ...

Relmada Therapeutics has expressed its commitment to closely monitoring the bid price during the Compliance Period and taking necessary actions to meet Nasdaq’s listing requirements ...